We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Celadon Pharmaceuticals Plc | LSE:SWC | London | Ordinary Share | Ordinary Shares |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 147.50 | 140.00 | 155.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSWC
RNS Number : 9267T
Summerway Capital PLC
29 November 2021
29 November 2021
Summerway Capital Plc
("Summerway" or the "Company")
Change in Accounting Reference Date
The Board of Directors of Summerway Capital Plc (AIM: SWC) today announces that it will be changing its accounting reference date and financial year end from 31 August to 31 December.
The accounting reference date change to 31 December has been made to align the Company's accounting reference date with that of Vertigrow Technologies Ltd, the proposed acquisition announced on 28 October 2021.
As a result, the Company's next financial reporting events will be as follows:
-- Publication of interim results for the 12 months to 31 August 2021, not later than 30 November 2021;
-- Publication of audited accounts for the 16 month period to 31 December 2021, not later than 30 April 2022; and
-- Publication of interim results for the 6 months ended 30 June 2022, not later than 30 September 2022.
Enquiries:
Summerway Capital Plc
Tony Morris 020 7440 7520 Canaccord Genuity Limited (Nominated Adviser and Broker) Andrew Potts 020 7523 8000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCDKCBDPBDDQDB
(END) Dow Jones Newswires
November 29, 2021 10:16 ET (15:16 GMT)
1 Year Celadon Pharmaceuticals Chart |
1 Month Celadon Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions